ABIVAX Société Anonyme (NASDAQ:ABVX) Receives $38.67 Consensus Target Price from Analysts

ABIVAX Société Anonyme (NASDAQ:ABVX) has been given an average rating of “Buy” by the seven research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $38.67.

A number of equities analysts recently weighed in on ABVX shares. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. JMP Securities restated a “market outperform” rating and set a $33.00 target price on shares of ABIVAX Société Anonyme in a report on Friday, January 10th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC raised its position in ABIVAX Société Anonyme by 190.1% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company’s stock valued at $11,078,000 after purchasing an additional 991,781 shares during the period. Franklin Resources Inc. lifted its position in ABIVAX Société Anonyme by 10.7% in the fourth quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company’s stock valued at $10,732,000 after buying an additional 141,710 shares during the last quarter. Nantahala Capital Management LLC boosted its stake in ABIVAX Société Anonyme by 45.7% during the fourth quarter. Nantahala Capital Management LLC now owns 1,436,047 shares of the company’s stock worth $10,512,000 after buying an additional 450,413 shares during the period. Millennium Management LLC increased its position in shares of ABIVAX Société Anonyme by 44.2% during the fourth quarter. Millennium Management LLC now owns 931,179 shares of the company’s stock valued at $6,816,000 after acquiring an additional 285,542 shares during the last quarter. Finally, Citadel Advisors LLC raised its stake in shares of ABIVAX Société Anonyme by 83.5% in the 4th quarter. Citadel Advisors LLC now owns 855,676 shares of the company’s stock valued at $6,264,000 after acquiring an additional 389,247 shares during the period. 47.91% of the stock is currently owned by institutional investors and hedge funds.

ABIVAX Société Anonyme Stock Up 6.0 %

Shares of ABVX opened at $8.08 on Monday. ABIVAX Société Anonyme has a 52-week low of $5.49 and a 52-week high of $17.02. The firm’s fifty day moving average is $6.83 and its two-hundred day moving average is $9.14.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.